Artax Biopharma Inc. is thrilled to announce the successful completion of an $8 million funding round, a significant milestone that will propel the company's innovative research forward. As a trailblazer in the biopharmaceutical sector, Artax Biopharma specializes in developing new treatments for autoimmune and inflammatory diseases. Our dedicated team is currently focused on pioneering a next-generation class of drugs that target the interaction between T cell receptor (TCR) and Nck—an essential process for T cell activation. This breakthrough approach has the potential to yield first-in-class immunomodulators, uniquely positioned to address a wide array of challenging health conditions that currently lack effective therapies. The newly raised capital will be instrumental in advancing our clinical studies, accelerating product development and expanding our research capabilities. By refining our targeted compounds, we aim not only to improve patient outcomes but also to fill a critical void in the existing medical landscape. As an organization committed to empowering individuals struggling with autoimmune disorders, we are optimistic that this funding will help bring transformative solutions to market. We express our heartfelt gratitude to our investors for their trust and support in our mission to revolutionize treatment approaches in this vital field. Exciting developments are on the horizon, and we look forward to sharing more updates as we progress on this journey of innovation and patient care.
Artax Biopharma Inc Secures $8 Million in Funding to Advance Next-Generation Immunomodulators for Autoimmune and Inflammatory Diseases
Recently funded · $8.0MBiotechnology
Get the full Artax Biopharma Inc company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
